Detalles de la búsqueda
1.
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs.
Haemophilia
; 29(3): 809-818, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148500
2.
Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses.
Eur Child Adolesc Psychiatry
; 30(5): 809-821, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32691164
3.
Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
J Manag Care Spec Pharm
; 29(6): 626-634, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37276033
4.
Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data.
J Med Econ
; 26(1): 1278-1286, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37787429
5.
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
J Med Econ
; 25(1): 755-761, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35611840
6.
The Association of Oral Stimulant Medication Adherence with Work Productivity among Adults with ADHD.
J Atten Disord
; 26(6): 831-842, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34137280
7.
Economic Burden Associated with Major Surgery in Patients with von Willebrand Disease: A United States Retrospective Administrative Database Analysis.
J Blood Med
; 12: 699-708, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34393536
8.
Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
J Manag Care Spec Pharm
; 27(2): 175-185, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33307935
9.
Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA.
CNS Drugs
; 35(5): 575-589, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33856656
10.
Healthcare provider perspectives on diagnosing and treating adults with attention-deficit/hyperactivity disorder.
Postgrad Med
; 131(7): 461-472, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31340712
11.
Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.
Am J Manag Care
; 24(8 Suppl): S156-S164, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693362
12.
Re: Response letter to Sanofi's communication related to "the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States".
J Med Econ
; 26(1): 581-583, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068171
13.
Assessment of the relationship between diabetes treatment intensification and quality measure performance using electronic medical records.
PLoS One
; 13(6): e0199011, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29894495
14.
Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Curr Med Res Opin
; 33(10): 1869-1877, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28613952
15.
Economic burden of comorbid chronic kidney disease and diabetes.
J Med Econ
; 20(6): 585-591, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28128669
Resultados
1 -
15
de 15
1
Próxima >
>>